Scancell Holdings (LON:SCLP) , the cancer vaccine developer, announced that its collaboration with ImmuneRegen BioSciences (announced in June 2010) is already bearing some fruit. The companies have tested an ImmunoBody based DNA vaccine in combination with ImmuneRegen's Homspera vaccine adjuvant technology in an animal model. The results of this test indicate that Homspera increased the immune response over that of the DNA vaccine alone. Scancell's first ImmunoBody vaccine candidate, SCIB1 for melanoma, is currently in Phase I clinical trials in the UK. The Homspera compound was previously shown to increase the immune response of another potential melanoma (TRP-2 encoding) DNA vaccine. The ultimate aim of the collaboration between Scancell and ImmuneRegen is to develop a next generation melanoma vaccine therapy. The company also announced that it has appointed Matrix Corporate Capital LLP as joint broker along with Zeus Capital.
The SCLP share price has increased by 96% over the last year. Scancell Holdings Plc is currently graded c by LCF Research.
This note was prepared by LCF Research Limited using information provided by the subject company’s management or publically available news sources. No representations are made nor warranties given (express or implied) in relation to accuracy and completeness. This document is not an invitation to invest in the subject company and does not purport to contain all the necessary information that a prospective investor might require. LCF Research Limited recommends prospective investors to conduct their own thorough independent analysis of the subject company and the information contained in this note or referred to above.